Basic and Clinical Aspects of Copper

Critical Reviews in Clinical Laboratory Sciences

Volumn 40, Issue 5, 2003, Pages 547-586

  Harris, Edward D ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Aceruloplasminemia; Alzheimer disease; Amyotrophic lateral sclerosis; Angiogenesis; Copper metabolism; Copper transport; Menkes disease; Parkinson disease; Prion disease; Wilson disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID BETA PROTEIN; COPPER; GLUTATHIONE; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; CELL MEMBRANE TRANSPORT; CLINICAL TRIAL; COPPER METABOLISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; MENKES SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; REVIEW; WILSON DISEASE;

EID: 0344945623     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360390250649     Document Type: Review

References (306)

1. Kies C, ed. Copper Bioavailability and Metabolism. Advances in Experimental Medicine and Biology, no. 258. New York: Plenum Press, 1989.
2. Linder MC. Biochemistry of Copper. New York: Plenum Press, 1991.
3. Vulpe CD, Packman S. Cellular copper transport. Annu Rev Nutr 1995; 15: 293-322.
4. Harris ED. Cellular copper transport and metabolism. Annu Rev Nutr 2000; 20: 291-310.
5. Abderhalden E. Die beziehungen des eisens zur blutbidung. Z Biol 1900; 39: 482-523.
6. Hart EB, Steenbock H, Elvehjem CA, et al. Iron in nutrition. I. Nutritional anemia on whole milk diets and the utilization of inorganic iron in hemoglobin building. J Biol Chem 1925; 65: 67-80.
7. Waddell J, Elvehjem CA, Steenbock H, et al. Iron in nutrition. VI. Iron salts and iron-containing ash extracts in the correction of anemia. J Biol Chem 1927; 77: 777-95.
8. Hart EB, Elvehjem CA, Waddell J, et al. Iron in nutrition. IV. Nutritional anemia on whole milk diets and its correction with the ash of certain plant and animal tissues or with soluble iron salts. J Biol Chem 1927; 72: 299-320.
9. Hart EB, Steenbock H, Waddell J, et al. Iron in nutrition. VII. Copper as a supplement to iron for hemoglobin building in the rat. J Biol Chem 1928; 77: 797-812.
10. Elvehjem CA, Hart EB. The relation of iron and copper to hemoglobin synthesis in the chick. J Biol Chem 1929; 84: 131-41.
11. Elvehjem CA, Hart EB. The necessity of copper as a supplement to iron for hemoglobin formation in the pig. J Biol Chem 1932; 95: 363-70.
12. Mills ES. The treatment of idiopathic (hypochromic) anaemia with iron and copper. Can Med Assoc J 1930; 22: 175-8.
13. Elvehjem CA, Duckles D, Mendenhall DR. Iron versus iron and copper in the treatment of anemia in infants. Am J Dis Child 1937; 53: 758-93.
14. Bennetts HW, Chapman FE. Copper deficiency in sheep in Western Australia: a preliminary account of the aetiology of enzootic ataxia of ewes. Aust Vet J 1937; 13: 138-49.
15. Bennetts HW, Harley R, Evans ST. Studies on copper deficiency of cattle: the fatal termination ("falling disease"). Austr Vet J 1942; 18: 50-63.
16. Holmberg CG, Laurell CB. Investigations in serum copper. I. Nature of serum copper and its relation to the iron-binding protein in human serum. Acta Chem Scand 1947; 82: 944-50.
17. Holmberg CG, Laurell CB. Investigations in serum copper. II. Isolation of the copper containing protein, and a description of some of its properties. Acta Chem Scand 1948; 2: 550-6.
18. Curzon G, O'Reilly S. A coupled iron-ceruloplasmin oxidation system. Biochem Biophys Res Commun 1960; 2: 284-6.
19. Osaki S, Johnson DA. Mobilization of liver iron by ferroxidase (ceruloplasmin). J Biol Chem 1969; 244: 5757-8.
20. Ragan HA, Nacht S, Lee GR, et al. Effect of ceruloplasmin on plasma iron in copper-deficient swine. Am J Physiol 1969; 217: 1320-3.
21. Osaki S, Johnson DA, Frieden E. The possible significance of the ferroxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241: 2746-51.
22. Scheinberg IH, Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease). Science 1952; 116: 484.
23. Davis GK, Mertz W. Copper. In: Mertz W, ed. Trace Elements in Human and Animal Nutrition, Vol 1. pp. 301-64. San Diego: Academic Press, 1987.
24. O'Dell BL, Hardwick BC, Reynolds G, et al. Connective tissue defect in the chick resulting from copper deficiency. Proc Soc Exp Biol Med 1961; 108: 402-5.
25. Coulson WF, Carnes WH. Cardiovascular studies on copper-deficient swine. Am J Pathol 1961; 43: 945-54.
26. Dancis A, Yuan DS, Haile D, et al. Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport. Cell 1994; 76: 393-402.
27. Frazer DM, Vulpe CD, Mckie AT, et al. Cloning and gastrointestinal expression of rat hephaestin: relationship to other iron transport proteins. Am J Physiol Gastrointest Liver Physiol 2001; 281: G931-9.
28. Vulpe CD, Kuo YM, Murphy TL, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21: 195-9.
29. Lin SJ, Culotta VC. The ATX1 gene of Saccharomyces cerevisiae encodes a small metal homeostasis factor that protects cells against reactive oxygen toxicity. Proc Natl Acad Sci USA 1995; 92: 3784-8.
30. Valentine JS, Gralla EB. Delivering Cu inside yeast cells. Science 1997; 278: 817-8.
31. Petris MJ, Mercer JF. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet 1999; 8: 2107-15.
32. Harris DIM, Sass-Kortsak A. The influence of amino acids on copper uptake by rat liver slices. J Clin Invest 1967; 46: 659-77.
33. Darwish HM, Hoke JE, Ettinger MJ. Kinetics of Cu(II) transport and accumulation by hepatocytes from copper-deficient mice and the brindled mouse model of Menkes disease. J Biol Chem 1983; 258: 13621-6.
34. 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity high capacity process. J Biol Chem 1988; 263: 799-805.
35. Waldrop GL, Ettinger MJ. Effects of albumin and histidine on kinetics of copper transport by fibroblasts. Am J Physiol Gastrointest Liver Physiol 1990; 259: G212-8.
36. 67copper uptake and of copper stimulation of the release of luteinizing hormone-releasing hormone from median eminence explants. Brain Res 1991; 541: 93-7.
37. Orena SJ, Goode CA, Linder MC. Binding and uptake of copper from ceruloplasmin. Biochem Biophys Res Commun 1986; 139: 822-9.
38. Percival SS, Harris ED. Copper transport from ceruloplasmin: Characterization of the cellular uptake mechanism. Am J Physiol 1990; 258: C140-6.
39. Dameron CT, Harris ED. Regulation of aortic Cu,Zn-superoxide dismutase with copper. Ceruloplasmin and albumin transfer copper and reactivate the enzyme in culture. Biochem J 1987; 248: 669-75.
40. Darwish HM, Schmitt RC, Cheney JC, et al. Copper efflux kinetics from rat hepatocytes. Am J Physiol 1984; 246: G48-55.
41. Qian Y, Tiffany-Castiglioni E, Welsh J, et al. Copper efflux from murine microvascular cells requires expression of the Menkes disease Cu-ATPase. J Nutr 1998; 128: 1276-82.
42. Qian Y, Tiffany-Castiglioni E, Harris ED. Copper transport and kinetics in cultured C6 rat glioma cells. Am J Physiol 1995; 269: C892-8.
43. Qian Y, Tiffany-Castiglioni E, Harris ED. Functional analysis of a genetic defect of copper transport (Menkes disease) in different cell lines. Am J Physiol 1996; 271: C378-84.
44. Harris ED, Qian Y, Tiffany-Castiglioni E, et al. Functional analysis of copper homeostasis in cell culture models: a new perspective on internal copper transport. Am J Clin Nutr 1998; 67: 988S-95S.
45. Driessen AJM, Konings WN. Reactive exofacial sulfhydryl-groups on the arginine-ornithine antiporter of Lactococcus lactis. Biochim Biophys Acta 1990; 1015: 87-95.
46. Dancis A, Roman DG, Anderson GJ, et al. Ferric reductase of Saccharomyces cerevisiae: Molecular characterization, role in iron uptake, and transcriptional control by iron. Proc Natl Acad Sci USA 1992; 89: 3869-73.
47. Askwith C, Eide D, Van Ho A, et al. The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake. Cell 1994; 76: 403-10.
48. Dancis A, Haile D, Yuan DS, et al. The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J Biol Chem 1994; 269: 25660-7.
49. Knight SAB, Labbé S, Kwon LF, et al. A widespread transposable element masks expression of a yeast copper transport gene. Genes Dev 1996; 10: 1917-29.
50. Labbe S, Zhu Z, Thiele DJ. Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway. J Biol Chem 1997; 272: 15951-8.
51. Labbe S, Pena MM, Fernandes AR, et al. A copper-sensing transcription factor regulates iron uptake genes in Schizosaccharomyces pombe. J Biol Chem 1999; 274: 36252-60.
52. Beaudoin J, Labbe S. The fission yeast copper-sensing transcription factor Cuf1 regulates the copper transporter gene expression through an Ace1/Amt1-like recognition sequence. J Biol Chem 2001; 276: 15472-80.
53. Lee J, Prohaska JR, Dagenais SL, et al. Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 2000; 254: 87-96.
54. Lee J, Pena MM, Nose Y, et al. Biochemical characterization of the human copper transporter Ctr1. J Biol Chem 2002; 277: 4380-7.
55. Fleming MD, Trenor CC, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16: 383-6.
56. Su MA, Trenor CC, Fleming JC, et al. The G185R mutation disrupts function of the iron transporter Nramp2. Blood 1998; 92: 2157-63.
57. Harrison MD, Jones CE, Dameron CT. Copper chaperones: function, structure and copper-binding properties. J Biol Inorg Chem 1999; 4: 145-53.
58. Rae TD, Schmidt PJ, Pufahl RA, et al. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999; 284: 805-8.
59. Huffman DL, O'Halloran TV. Function, structure, and mechanism of intracellular copper trafficking proteins. Annu Rev Biochem 2002; 70: 677-701.
60. Steinbach OM, Wolterbeek HT. Role of cytosolic copper, metallothionein and glutathione in copper toxicity in rat hepatoma tissue culture cells. Toxicology 1994; 92: 75-90.
61. Tong KK, McArdle HJ. Copper uptake by cultured trophoblast cells isolated from human term placenta. Biochim Biophys Acta 1995; 1269: 233-6.
62. Freedman JH, Ciriolo MR, Peisach J. The role of glutathione in copper metabolism and toxicity. J Biol Chem 1989; 264: 5598-605.
63. Freedman JH, Peisach J. Intracellular copper transport in cultured hepatoma cells. Biochem Biophys Res Commun 1989; 164: 134-40.
64. Ciriolo MR, Desideri A, Paci M, et al. Reconstitution of Cu, Zn-superoxide dismutase by the Cu(I)• glutathione complex. J Biol Chem 1990; 265: 11030-4.
65. 2+ and ATP. J Biol Chem 1996; 271: 1972-8.
66. Klomp LW, Lin SJ, Yuan DS, et al. Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem 1997; 272: 9221-6.
67. Hamza I, Schaefer M, Klomp LW, et al. Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. Proc Natl Acad Sci USA 1999; 96: 13363-8.
68. Lin SJ, Pufahl RA, Dancis A, et al. A role for the saccharomyces cerevisiae ATX1 gene in copper trafficking and iron transport. J Biol Chem 1997; 272: 9215-20.
69. Hamza I, Klomp LW, Gaedigk R, et al. Structure, expression, and chromosomal location of the mouse Atox1 gene. Genomics 2000; 63: 294-7.
70. Himelblau E, Mira H, Lin SJ, et al. Identification of a functional homolog of the yeast copper homeostasis gene ATX1 from Arabidopsis. Plant Physiol 1998; 117: 1227-34.
71. Wakabayashi T, Nakamura N, Sambongi Y, et al. Identification of the copper chaperone, CUC-1, in Caenorhabditis elegans: tissue specific co-expression with the copper transporting ATPase, CUA-1. FEBSLett 1998; 440: 141-6.
72. Lockhart PJ, Mercer JF. Identification of the copper chaperone SAH in Ovis aries: expression analysis and in vitro interaction of SAH with ATP7B. Biochim Biophys Acta 2000; 1490: 11-20.
73. Portnoy ME, Rosenzweig AC, Rae T, et al. Structure-function analyses of the ATX1 metallochaperone. J Biol Chem 1999; 274: 15041-5.
74. Kelner GS, Lee M, Clark ME, et al. The copper transport protein Atox1 promotes neuronal survival. J Biol Chem 2000; 275: 580-4.
75. Culotta VC, Klomp LW, Strain J, et al. The copper chaperone for superoxide dismutase. J Biol Chem 1997; 272: 23469-72.
76. Culotta VC, Lin S-J, Schmidt P, et al. Intracellular pathways of copper trafficking in yeast and humans. Adv Exp Med Biol 1999; 448: 247-54.
77. Silahtaroglu AN, Brondum-Nielsen K, Gredal O, et al. Human CCS gene: genomic organization and exclusion as a candidate for amyotrophic lateral sclerosis (ALS). BMC Genet 2002; 3: 5.
78. Schmidt PJ, Rae TD, Pufahl RA, et al. Multiple protein domains contribute to the action of the copper chaperone for superoxide dismutase. J Biol Chem 1999; 274: 23719-25.
79. Hiromura M, Chino H, Sonoda T, et al. Molecular cloning and characterization of a copper chaperone for copper/zinc superoxide dismutase from the rat. Biochem Biophys Res Commun 2000; 275: 394-400.
80. Petruzzella V, Tiranti V, Fernandez P, et al. Identification and characterization of human cDNAs specific to BCS1, PET112, SCO1, COX15, and COX11, five genes involved in the formation and function of the mitochondrial respiratory chain. Genomics 1998; 54: 494-504.
81. Glerum DM, Shtanko A, Tzagoloff A. Characterization of COX17, a yeast gene involved in copper metabolism and assembly of cytochrome oxidase. J Biol Chem 1996; 271: 14504-9.
82. Amaravadi R. Glerum DM, Tzagoloff A. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum Genet 1997; 99: 329-33.
83. Punter FA, Adams DL, Glerum DM. Characterization and localization of human COX17, a gene involved in mitochondrial copper transport. Hum Genet 2000; 107: 69-74.
84. Srinivasan C, Posewitz MC, George GN, et al. Characterization of the copper chaperone Cox17 of Saccharomyces cerevisiae. Biochemistry 1998; 37: 7572-7.
85. Takenouchi T, Fujimoto M, Shimamoto A, et al. Isolation and characterization of Cox17p from porcine heart by determining its survival-promoting activity in NIH3T3 cells. Biochim Biophys Acta 1999; 1472: 498-508.
86. Heaton D, Nittis T, Srinivasan C, et al. Mutational analysis of the mitochondrial copper metallochaperone Cox17. J Biol Chem 2000; 275: 37582-7.
87. Kako K, Tsumori K, Ohmasa Y, et al. The expression of Cox17p in rodent tissues and cells. Eur J Biochem 2000; 267: 6699-707.
88. Glerum DM, Shtanko A, Tzagoloff A. SCO1 and SCO2 act as high copy suppressors of a mitochondrial copper recruitment defect in Saccharomyces cerevisiae. J Biol Chem 1996; 271: 20531-5.
89. Horvath R, Lochmuller H, Stucka R, et al. Characterization of human SCO1 and COX17 genes in mitochondrial cytochrome-c-oxidase deficiency. Biochem Biophys Res Commun 2000; 276: 530-3.
90. Chinenov YV. Cytochrome c oxidase assembly factors with a thioredoxin fold are conserved among prokaryotes and eukaryotes. J Mol Med 2000; 78: 239-42.
91. Fischer PWF, L'Abbe MR. Copper transport by intestinal brush border membrane vesicles from rats fed high zinc or copper deficient diets. Nutr Res 1985; 5: 759-67.
92. Dinsdale D, Holt D, Webb M. Intestinal uptake and retention of copper in the suckling rat, rattus rattus. II. Copper accumulation in the ileum and distal jejunum. Comp Biochem Physiol 1986; 83C: 317-23.
93. Ballan-Dufrançais C, Marcaillou C, Amiard-Triquet C. Response of the phytoplactonic alga tetraselmis suecica to copper and silver exposure: vesicular metal bioaccumulation and lack of starch bodies. Biol Cell 1991; 72: 103-12.
94. Szczypka MS, Zhu Z, Silar P, et al. Saccharomyces cerevisiae mutants altered in vacuole function are defective in copper detoxification and iron-responsive gene transcription. Yeast 1997; 13: 1423-35.
95. Davidson LA, McOrmond SL, Harris ED. Characterization of a particulate pathway for copper in K562 cells. Biochim Biophys Acta 1994; 1221: 1-6.
96. Dierick HA, Adam AN, Escara-Wilke JF, et al. Immunocytochemical localization of the Menkes copper transport protein (ATP7A) to the trans-Golgi network. Hum Mol Genet 1997; 6: 409-16.
97. La Fontaine S, Firth SD, Lockhart PJ, et al. Functional analysis and intracellular localization of the human Menkes protein (MNK) stably expressed from a cDNA construct in Chinese hamster ovary cells (CHO-K1). Hum Mol Genet 1998; 7: 1293-300.
98. Solioz M, Mathews S, Fürst P. Cloning of the K+-ATPase of Streptococcus faecalis. Structural and evolutionary implications of its homology to the KdpB-protein of Escherichia coli. J Biol Chem 1987; 262: 7358-62.
99. Silver S, Nucifora G, Phung LT. Human Menkes X-chromosome disease and the staphylococcal cadmium-resistance ATPase: a remarkable similarity in protein sequences. Mol Microbiol 1993; 10: 7-12.
100. Odermatt A, Suter H, Krapf R, et al. An ATPase operon involved in copper resistance by Enterococcus hirae. Ann NY Acad Sci 1992; 671: 484-6.
101. Odermatt A, Suter H, Krapf R, et al. Primary structure of two P-type ATPases involved in copper homeostasis in Enterococcus hirae. J Biol Chem 1993; 268: 12775-9.
102. Solioz M, Vulpe C. Cpx-type ATPases: a class of P-type ATPases that pump heavy metals. Trends Biochem Sci 1996; 21: 237-41.
103. Axelsen KB, Palmgren MG. Evolution of substrate specificities in the P-type ATPase superfamily. J Mol Evol 1998; 46: 84-101.
104. Voskoboinik I, Mar J, Strausak D, et al. The regulation of catalytic activity of the Menkes copper-translocating P-type ATPase. Role of high affinity copper-binding sites. J Biol Chem 2001; 276: 28620-7.
105. Lutsenko S, Kaplan JH. Organization of P-type ATPases: Significance of structural diversity. Biochemistry 1995; 34: 15607-13.
106. Yuan DS, Stearman R, Dancis A, et al. The Menkes/Wilson disease gene homologue in yeast provides copper to a ceruloplasmin-like oxidase required for iron uptake. Proc Natl Acad Sci USA 1995; 92: 2632-6.
107. Yuan DS, Dancis A, Klausner RD. Restriction of copper export in Saccharomyces cerevisiae to a late Golgi or Post-Golgi compartment in the secretory pathway. J Biol Chem 1997; 272: 25787-93.
108. Tsivkovskii R, Hisses JF, Kaplan JH, et al. Functional properties of the copper-transporting ATPase ATP7B (the Wilson's disease protein) expressed in insect cells. J Biol Chem 2002; 277: 976-83.
109. Camakaris J, Petris MJ, Bailey L, et al. Gene amplification of the Menkes (MNK; ATP7A) P-type ATPase gene of CHO cells is associated with copper resistance and enhanced copper efflux. Hum Mol Genet 1995; 4: 2117-23.
110. Yamaguchi Y, Heiny ME, Suzuki M, et al. Biochemical characterization and intracellular localization of the Menkes disease protein. Proc Natl Acad Sci USA 1996; 93: 14030-5.
111. Ackland L, Cornish EJ, Paynter JA, et al. Expression of Menkes disease gene in mammary carcinoma cells. Biochem J 1997; 328: 237-43.
112. Francis MJ, Jones EE, Levy ER, et al. A Golgi localization signal identified in the Menkes recombinant protein. Hum Mol Genet 1998; 7: 1245-52.
113. Petris MJ, Voskoboinik I, Cater M, et al. Copper-regulated trafficking of the Menkes disease copper ATPase is associated with formation of a phosphorylated catalytic intermediate. J Biol Chem 2002; 277: 46736-42.
114. Petris MJ, Mercer JFB, Culvenor JG, et al. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO J 1996; 15: 6084-95.
115. Ambrosini L, Mercer JF. Defective copper-induced trafficking and localization of the Menkes protein in patients with mild and copper-treated classical Menkes disease. Hum Mol Genet 1999; 8: 1547-55.
116. La Fontaine S, Firth SD, Lockhart PJ, et al. Intracellular localization and loss of copper responsiveness of Mnk, the murine homologue of the Menkes protein, in cells from blotchy (Mo blo) and brindled (Mo br) mouse mutants. Hum Mol Genet 1999; 8: 1069-75.
117. Petris MJ, Camakaris J, Greenough M, et al. A C-terminal di-leucine is required for localization of the Menkes protein in the trans-Golgi network. Hum Mol Genet 1998; 7: 2063-71.
118. Francis MJ, Jones EE, Levy ER, et al. Identification of a di-leucine motif within the C terminus domain of the Menkes disease protein that mediates endocytosis from the plasma membrane. J Cell Sci 1999; 112: 1721-32.
119. Dagenais SL, Adam AN, Innis JW, et al. A novel frameshift mutation in exon 23 of ATP7A (MNK) results in occipital horn syndrome and not in Menkes disease. Am J Hum Genet 2001; 69: 420-7.
120. La Fontaine S, Firth SD, Camakaris J, et al. Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J Biol Chem 1998; 273: 31375-80.
121. Petris MJ, Strausak D, Mercer JF. The Menkes copper transporter is required for the activation of tyrosinase. Hum Mol Genet 2000; 9: 2845-51.
122. Tchaparian EH, Uriu-Adams JY, Keen CL, et al. Lysyl oxidase and P-ATPase-7A expression during embryonic development in the rat. Arch Biochem Biophys 2000; 379: 71-7.
123. Qian Y, Tiffany-Castiglioni E, Harris ED. Sequence of a Menkes-type Cu-transporting ATPAse from rat C6 glioma cells: comparison of the rat protein with other mammalian Cu-transporting ATPases. Mol Cell Biochem 1998; 181: 49-61.
124. Strausak D, La Fontaine S, Hill J, et al. The role of GMXCXXC metal binding sites in the copper-induced redistribution of the Menkes protein. J Biol Chem 1999; 274: 11170-7.
125. Forbes JR, Hsi G, Cox DR. Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease. J Biol Chem 1999; 274: 12408-13.
126. Vulpe C, Levinson B, Whitney S, et al. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993; 3: 7-13.
127. Mercer JFB, Livingston J, Hall B, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet 1993; 3: 20-5.
128. Paynter JA, Grimes A, Lockhart P, et al. Expression of the Menkes gene homologue in mouse tissues: lack of effect of copper on the mRNA levels. FEBS Lett 1994; 351: 186-90.
129. Kuo YM, Gitschier J, Packman S. Developmental expression of the mouse mottled and toxic milk genes suggests distinct functions for the Menkes and Wilson disease copper transporters. Hum Mol Genet 1997; 6: 1043-9.
130. Qian Y, Majumdar S, Reddy MCM, et al. Coincident expression of Menkes gene with copper efflux in human placental cells. Am J Physiol 1996; 270: C1880-4.
131. Levinson B, Conant R, Schnur R, et al. A repeated element in the regulatory region of the MNK gene and its deletion in a patient with occipital horn syndrome. Hum Mol Genet 1996; 5: 1737-42.
132. Oh WJ, Kim EK, Park KD, et al. Cloning and characterization of the promoter region of the Wilson Disease gene. Biochem Biophys Res Commun 1999; 259: 206-11.
133. Oh WJ, Kim EK, Ko JH, et al. Nuclear proteins that bind to metal response element a (MREa) in the Wilson disease gene promoter are Ku autoantigens and the Ku-80 subunit is necessary for basal transcription of the WD gene. Eur J Biochem 2002; 269: 2151-61.
134. Petrukhin K, Lutsenko S, Chernov I, et al. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Molec Genet 1994; 3: 1647-56.
135. Reddy MCM, Harris ED. Multiple transcripts coding for the Menkes gene: evidence for alternative splicing of Menkes mRNA. Biochem J 1998; 334: 71-7.
136. Harris ED, Reddy MCM, Majumdar S. Menkes gene: a potential locus for copper metabolism. J Trace Elem Exp Med 1999; 12: 331-5.
137. Lutsenko S, Cooper MJ. Localization of the Wilson's disease protein product to mitochondria. Proc Natl Acad Sci USA 1998; 95: 6004-9.
138. Harris ED, Reddy MCM, Qian Y, et al. Multiple forms of the Menkes Cu-ATPAse. Adv Exp Med Biol 1999; 448: 39-51.
139. Alvarez C, Fujita H, Hubbard A, et al. ER to Golgi transport: Requirement for p115 at a pre-Golgi VTC stage. J Cell Biol 1999; 147: 1205-22.
140. Voskoboinik I, Brooks H, Smith S, et al. ATP-dependent copper transport by the Menkes protein in membrane vesicles isolated from cultured Chinese hamster ovary cells. FEBS Lett 1998; 435: 178-82.
141. Bingham MJ, Ong TJ, Ingledew WJ, et al. ATP-dependent copper transporter, in the Golgi apparatus of rat hepatocytes, transports Cu(II), not Cu(I). Am J Physiol 1996; 271: G741-6.
142. Krupka RM. Coupling mechanisms in ATP-driven pumps. Biochim Biophys Acta 1993; 1183: 114-22.
143. Voskoboinik I, Strausak D, Greenough M, et al. Functional analysis of the N-terminal CXXC metal-binding motifs in the human Menkes copper-transporting P-type ATPase expressed in cultured mammalian cells. J Biol Chem 1999; 274: 22008-12.
144. Danks DM. Disorders of copper transport. In: Souver CR, Beaudet AL, Shy WM, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, pp. 2211-35. New York: McGraw-Hill, 1995.
145. Nagano K, Nakamura K, Urakami K-I, et al. Intracellular distribution of the Wilson's disease gene product (ATPase7B) after in vitro and in vivo exogenous expression in hepatocytes from the LEC rat, an animal model of Wilson's disease. Hepatology 1998; 27: 799-807.
146. Roelofsen H, Wolters H, Van Luyn MJ, et al. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterology 2000; 119: 782-93.
147. Chowrimootoo GF, Ahmed HA, Seymour CA. New insights into the pathogenesis of copper toxicosis in Wilson's disease: evidence for copper incorporation and defective canalicular transport of caeruloplasmin. Biochem J 1996; 315 (Pt 3): 851-5.
148. Davis W, Chowrimootoo GF, Seymour CA. Defective biliary copper excretion in Wilson's disease: the role of caeruloplasmin. Eur J Clin Invest 1996; 26: 893-901.
149. Ellis PP. Ocular deposition of copper in hypercupremia. Am J Opthalmol 1969; 68: 423-7.
150. Kuo Y-M, Gitschier J, Packman S. Developmental expression of the mouse mottled and toxic milk genes suggests distinct functions for the Menkes and Wilson disease copper transporters. Hum Molec Genet 1997; 6: 1043-9.
151. Petrukhin K, Fischer SG, Pirastu M, et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993; 5: 338-43.
152. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson's disease. Biochem Biophys Res Commun 1993; 197: 271-7.
153. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-36.
154. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344-50.
155. Thomas GR, Roberts EA, Walshe JM, et al. Haplotypes and mutations in Wilson disease. Am J Hum Genet 1995; 5675: 1315-9.
156. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995; 9: 210-7.
157. Brewer GJ. Wilson disease and canine copper toxicosis. Am J Clin Nutr 1998; 67: 1087S-90S.
158. Rauch H. Toxic milk, a new mutation affecting copper metabolism in the mouse. J Hered 1983; 74: 141-4.
159. Mercer JFB, Grimes A, Danks DM, et al. Hepatic ceruloplasmin gene expression is unaltered in the toxic milk mouse. J Nutr 1991; 121: 894-9.
160. Li Y, Togashi Y, Sato S, et al. Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease. J Clin Invest 1991; 87: 1858-61.
161. Sato M, Hachiya N, Yamaguchi Y, et al. Deficiency of holo-, but not apo-, ceruloplasmin in genetically copper-intoxicated LEC mutant rat. Life Sci 1993; 53: 1411-6.
162. Fujii Y, Shimizu K, Satoh M, et al. Histochemical demonstration of copper in LEC rat liver. Histochemistry 1993; 100: 249-56.
163. Sato M, Sugiyama T, Daimon T, et al. Histochemical evidence for abnormal copper distribution in the central nervous system of LEC mutant rat. Neurosci Lett 1994; 171: 97-100.
164. Harris ED. Biological monitoring of iron, zinc, and copper. In: Dillon HK, Ho MH, eds. Biological Monitoring of Exposure to Chemicals: Metals, pp. 175-96. New York: John Wiley & Sons, 1991.
165. Murata Y, Yamakawa E, Iizuka T, et al. Failure of copper incorporation into ceruloplasmin in the Golgi apparatus of LEC rat hepatocytes. Biochem Biophys Res Commun 1995; 209: 349-55.
166. Nakamura K, Endo F, Ueno T, et al. Excess copper and ceruloplasmin biosynthesis in long-term cutlured hepatocytes from Long-Evans Cinnamon (LEC) rats, a model of Wilson disease. J Biol Chem 1995; 270: 7656-60.
167. Schilsky ML, Irani AN, Gorla GR, et al. Biliary copper excretion capacity in intact animals: correlation between ATP7B function, hepatic mass, and biliary copper excretion. J Biochem Mol Toxicol 2000; 14: 210-4.
168. Terada K, Nakako T, Yang X-L, et al. Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA. J Biol Chem 1998; 273: 1815-20.
169. Terada K, Aiba N, Yang XL, et al. Biliary excretion of copper in LEC rat after introduction of copper transporting P-type ATPase, ATP7B. FEBS Lett 1999; 448: 53-6.
170. Ludwig J, Owen CAJ, Barham SS, et al. The liver in the inherited copper disease of Bedlington terriers. Lab Invest 1980; 43: 82-7.
171. Watson ADJ, Middleton DJ, Ilkiw JE. Copper storage disease with intravascular haemolysis in a Bedlington terrier. Aust Vet J 1983; 60: 305-7.
172. Owen CAJ, Ludwig J. Animal model of human disease. Inherited copper toxicosis in Bedlington Terriers. Wilson's disease (Hepatolenticular degeneration). Am J Pathol 1982; 106: 432-4.
173. Johnson GF, Gilbertson SR, Goldfischer S, et al. Cytochemical detection of inherited copper toxicosis of Bedlington Terriers. Vet Pathol 1984; 21: 57-60.
174. Stockert RJ, Morell AG, Sternlieb I. Purification of canine hepatic lysosomal copper-metallothionein. Methods Enzymol 1991; 205: 286-91.
175. Hunt DM, Wake SA, Mercer JFB, et al. A study of the role of metallothionein in the inherited copper toxicosis of dogs. Biochem J 1986; 236: 409-15.
176. Lerch K, Johnson GF, Grushoff PS, et al. Canine hepatic lysosomal copper protein: identification as metallothionein. Arch Biochem Biophys 1985; 243: 108-14.
177. Freedman JH, Powers L, Peisach J. Structure of the copper cluster in canine hepatic metallothionein using X-ray absorption spectroscopy. Biochemistry 1986; 25: 2342-9.
178. Nanji MS, Cox DW. The copper chaperone Atox1 in canine copper toxicosis in Bedlington terriers. Genomics 1999; 62: 108-12.
179. Muller T, van De Sluis B, Muller W, et al. Non-Indian childhood cirrhosis. Eur J Med Res 1999; 4: 293-7.
180. van de Sluis BJ, Breen M, Nanji M, et al. Genetic mapping of the copper toxicosis locus in Bedlington terriers to dog chromosome 10, in a region syntenic to human chromosome region 2p13-p16. Hum Mol Genet 1999; 8: 501-7.
181. van De Sluis B, Rothuizen J, Pearson PL, et al. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Hum Mol Genet 2002; 11: 165-73.
182. Baker A, Gormally S, Saxena R, et al. Copper-associated liver disease in childhood. J Hepatol 1995; 23: 538-43.
183. Prasad R, Kaur G, Nath R, et al. Molecular basis of pathophysiology of Indian childhood cirrhosis: Role of nuclear copper accumulation in liver. Mol Cell Biochem 1996; 156: 25-30.
184. Wijmenga C, Muller T, Murli IS, et al. Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease. Eur J Hum Genet 1998; 6: 624-8.
185. Menkes JH, Alter M, Steigleder GK, et al. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics 1962; 29: 764-79.
186. Danks DM, Campbell PE, Stevens BJ, et al. Menkes' kinky-hair syndrome: an inherited defect in copper absorption with widespread effects. Pediatrics 1972; 50: 188-201.
187. Danks DM, Campbell PE, Walker-Smith J, et al. Menkes' kinky-hair syndrome. Lancet 1972; 1: 1100-3.
188. Chelly J, Tümer Z, Tonnesen T, et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet 1993; 3: 14-9.
189. Dierick H, Ambrosini L, Spencer J, et al. Molecular structure of the Menkes disease gene (ATP7A). Genomics 1995; 28: 462-9.
190. Tumer Z, Vural B, Tonnesen T, et al. Characterization of the exon structure of the Menkes disease gene using vectorette PCR. Genomics 1995; 26: 437-42.
191. Tumer Z, Lund C, Tolshave J, et al. Identification of point mutations in 41 unrelated patients affected with Menkes disease. Am J Hum Genet 1997; 60: 63-71.
192. Moller LB, Tumer Z, Lund C, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am J Hum Genet 2000; 66: 1211-20.
193. Goka TJ, Stevenson RE, Hefferan PM, et al. Menkes disease: a biochemical abnormality in cultured human fibroblasts. Proc Natl Acad Sci USA 1976; 73: 604-6.
194. Horn N. Copper incorporation studies on cultured cells for prenatal diagnosis of Menkes' disease. Lancet 1976; 1: 1156-8.
195. Beratis NG, Yee M, LaBadie GU, et al. Effect of copper on Menkes' and normal cultured skin fibroblasts. Dev Pharmacol Ther 1980; 1: 305-17.
196. Riordan JR, Jolicoeur-Paquet L. Metallothionein accumulation may account for intracellular copper retention in Menkes' disease. J Biol Chem 1982; 257: 4639-45.
197. Tonnesen T, Horn N. Prenatal and postnatal diagnosis of Menkes disease, an inherited disorder of copper metabolism. J Inherit Metab Dis 1989; 12 (Suppl 1): 207-14.
198. Kodama H, Meguro Y, Abe T, et al. Genetic expression of Menkes disease in cultured astrocytes of the macular mouse. J Inherit Metab Dis 1991; 14: 896-901.
199. Garnica AD, Frias JL, Rennert OM. Menkes' kinky hair syndrome: is it a treatable disorder? Clin Genet 1977; 11: 154-61.
200. Kaler SG, Buist NR, Holmes CS, et al. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol 1995; 38: 921-8.
201. Christodoulou J, Danks DM, Sarkar B, et al. Early treatment of Menkes disease with parenteral copper-histidine: long-term follow-up of four treated patients. Am J Med Genet 1998; 76: 154-64.
202. Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int 1999; 41: 423-9.
203. Hunt DM. Primary defect in copper transport underlies mottled mutants in the mouse. Nature 1974; 249: 852-4.
204. Cecchi C, Avner P. Genomic organization of the mottled gene, the mouse homolog of the human Menkes disease gene. Genomics 1996; 37: 96-104.
205. Cecchi C, Biasotto M, Tosi M, et al. The mottled mouse as a model for human Menkes disease: Identification of mutations in the Atp7a gene. Hum Mol Genet 1997; 6: 425-33.
206. Levinson B, Vulpe C, Elder B, et al. The mottled gene is the mouse homologue of the Menkes disease gene. Nat Genet 1994; 6: 369-73.
207. Grimes A, Hearn CJ, Lockhart P, et al. Molecular basis of the brindled mouse mutant (Mo-br): A murine model of Menkes disease. Hum Molec Genet 1994; 6: 1037-42.
208. Mori M, Nishimura M. A serine-to-proline mutation in the copper-transporting P-type ATPase gene of the macular mouse. Mamm Genome 1997; 8: 407-10.
209. Murata Y, Kodama H, Abe T, et al. Mutation analysis and expression of the mottled gene in the macular mouse model of Menkes disease. FEBS Lett 1997; 412: 165-8.
210. Evans GW, Reiss BL. Impaired copper homeostasis in neonatal male and adult female brindled (Mobr) mice. J Nutr 1978; 108: 554-60.
211. Prins HW, van den Hamer CJA. Primary biochemical defect in copper metabolism in mice with a recessive X-linked mutation analogous to Menkes' disease in man. J Inorg Biochem 1979; 10: 19-27.
212. Shiraishi N, Aono K, Taguchi T. Copper metabolism in the macular mutant mouse: an animal model of Menkes' kinky-hair disease. Biol Neonate 1988; 54: 173-80.
213. Yoshimura N, Asada M, Kida K, et al. Chronological observations of histological changes, cytochrome oxidase activity and copper level in the brain of the postnatal brindled mouse. Acta Pathol Jap 1990; 40: 383-90.
214. Hunt DM, Johnson DR. An inherited defect in noradrenaline biosynthesis in the brindled mouse. J Neurochem 1972; 19: 2811-9.
215. Martin P, Ohno M, Southerland SB, et al. Heterotypic sprouting of serotonergic forebrain fibers in the brindled mottled mutant mouse. Dev Brain Res 1994; 77: 215-25.
216. Satoh J, Irino M, Martin PM, et al. Neurochemical and immunocytochemical studies of catecholamine system in the brindled mouse. J Neuropathol Exp Neurol 1991; 50: 793-808.
217. Prohaska JR. Changes in tissue growth, concentration of copper, iron, cytochrome oxidase and superoxide dismutase subsequent to dietary of genetic copper deficiency in mice. J Nutr 1983; 113: 2148-58.
218. Phillips M, Camakaris J, Danks DM. Comparisons of copper deficiency states in the murine mutants blotchy and brindled. Biochem J 1986; 238: 177-83.
219. Kuznetsov AV, Clark JF, Winkler K, et al. Increase in flux control of cytochrome c oxidase in copper-deficient mottled brindled mice. J Biol Chem 1996; 271: 283-8.
220. br) mice. Biochem J 1982; 202: 369-71.
221. Yoshimura N. Histochemical localization of copper in various organs of brindled mice. Pathol Int 1994; 44: 14-9.
222. br) mice. Biochem J 1979; 180: 605-12.
223. Wenk G, Suzuki K. The effect of copper supplementation on the concentration of copper in the brain of the brindled mouse. Biochem J 1982; 205: 485-7.
224. Shiraishi N, Taguchi T, Kinebuchi H. Copper-induced toxicity in macular mutant mouse: An animal model for Menkes' kinky-hair disease. Toxicol Appl Pharmacol 1991; 110: 89-96.
225. Fujii T, Ito M, Tsuda H, et al. Biochemical study on the critical period for treatment of the mottled brindled mouse. J Neurochem 1990; 55: 885-9.
226. Yoshimura N, Hatayama I, Sato K, et al. Complete recovery of cytochrome oxidase and superoxide dismutase activities in the brain of brindled mice receiving copper therapy. J Intellect Disabil Res 1993; 37: 561-7.
227. Yoshimura N, Kida K, Usutani S, et al. Histochemical localization of copper in various organs of brindled mice after copper therapy. Pathol Int 1995; 45: 10-8.
228. Mann JR, Camakaris J, Danks DM. Copper metabolism in mottled mouse mutants. Defective placental transfer of 64Cu to foetal brindled (Mobr) mice. Biochem J 1980; 186: 629-31.
229. Kodama H, Murata Y. Molecular genetics and pathophysiology of Menkes disease. Pediatr Int 1999; 41: 430-5.
230. Peltonen L, Kuivaniemi H, Palotie A, et al. Alterations in copper and collagen metabolism in the Menkes' syndrome and a new subtype of the Ehlers-Danlos syndrome. Biochemistry 1983; 22: 6156-63.
231. Kemppainen R, Hamalainen ER, Kuivaniemi H, et al. Expression of mRNAs for lysyl oxidase and type III procollagen in cultured fibroblasts from patients with the Menkes and occipital horn syndromes as determined by quantitative polymerase chain reaction. Arch Biochem Biophys 1996; 328: 101-6.
232. De Paepe A, Loeys B, Devriendt K, et al. Occipital horn syndrome in a 2-year-old boy. Clin Dysmorphol 1999; 8: 179-83.
233. Kaler SG, Das S, Levinson B, et al. Successful early copper therapy in Menkes disease associated with a mutant transcript containing a small in-frame deletion. Biochem Mol Med 1996; 57: 37-46.
234. Qi M, Byers PH. Constitutive skipping of alternatively spliced exon 10 in the ATP7A gene abolishes Golgi localization of the Menkes protein and produces the occipital horn syndrome. Hum Molec Genet 1998; 7: 465-9.
235. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol 1998; 1: 85-98.
236. Gu YH, Kodama H, Murata Y, et al. ATP7A gene mutations in 16 patients with Menkes disease and a patient with occipital horn syndrome. Am J Med Genet 2001; 99: 217-22.
237. Das S, Levinson B, Vulpe C, et al. Similar splicing mutations of the Menkes/Mottled copper-transporting ATPase gene in occipital horm syndrome and the blotchy mouse. Am J Hum Genet 1995; 56: 570-6.
238. Reed V, Boyd Y. Mutation analysis provides additional proof that mottled is the mouse homologue of Menkes' disease. Hum Mol Genet 1997; 6: 417-23.
239. Miyajima H, Kohno S, Takahashi Y, et al. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999; 53: 617-9.
240. Miyajima H, Nishimura Y, Mizoguchi K, et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761-7.
241. Okamoto N, Wada S, Oga T, et al. Hereditary ceruloplasmin deficiency with hemosiderosis. Hum Genet 1996; 97: 755-8.
242. Miyajima H, Fujimoto M, Kohno S, et al. CSF abnormalities in patients with aceruloplasminemia. Neurology 1998; 51: 1188-90.
243. Logan JI, Harveyson KB, Wisdom GB, et al. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. Q J Med 1994; 87: 663-70.
244. Yoshida K, Furihata K, Takeda S, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 267-72.
245. Yonekawa M, Okabe T, Asamoto Y, et al. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur Neurol 1999; 42: 157-62.
246. Takahashi Y, Miyajima H, Shirabe S, et al. Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative disease. Hum Mol Genet 1996; 5: 81-4.
247. Yazaki M, Yoshida K, Nakamura A, et al. A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. J Neurol Sci 1998; 156: 30-4.
248. Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995; 92: 2539-43.
249. Harris ZL, Durley AP, Man TK, et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999; 96: 10812-7.
250. Klomp LW, Gitlin JD. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 1996; 5: 1989-96.
251. Patel BN, David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 1997; 272: 20185-90.
252. Salzer JL, Lovejoy L, Linder MC, et al. Ran-2, a glial lineage marker, is a GPI-Anchored form of ceruloplasmin. J Neurosci Res 1998; 54: 147-57.
253. Miyajima H, Adachi J, Tatsuno Y, et al. Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 1998; 50: 130-6.
254. Attieh ZK, Mukhopadhyay CK, Seshadri V, et al. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem 1999; 274: 1116-23.
255. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis 1999; 6: 221-30.
256. Loske C, Gerdemann A, Schepl W, et al. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 2000; 267: 4171-8.
257. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 2000; 75: 1219-33.
258. Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 1997; 99: 245-56.
259. Togashi S, Lim SK, Kawano H, et al. Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 1997; 77: 525-31.
260. Curtain CC, Ali F, Volitakis I, et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane- penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001; 276: 20466-73.
261. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimers's disease in the reduction of copper(II) to copper (I). Science 1996; 271: 1406-9.
262. Atwood CS, Huang X, Khatri A, et al. Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol (Noisy-le-grand) 2000; 46: 777-83.
263. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000; 275: 19439-42.
264. Huang X, Cuajungco MP, Atwood CS, et al. Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 2000; 130: 1488S-92S.
265. White AR, Multhaup G, Maher F, et al. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 1999; 19: 9170-9.
266. Borchardt T, Camakaris J, Cappai R, et al. Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor- protein secretion. Biochem J 1999; 344(Pt 2): 461-7.
267. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
268. White AR, Reyes R, Mercer JF, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 1999; 842: 439-44.
269. Paik SR, Shin HJ, Lee JH, et al. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J 1999; 340: 821-8.
270. Kruger R, Muller T, Riess O. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders. J Neural Transm 2000; 107: 31-40.
271. Valentine JS, Hart PJ, Gralla EB. Copper-zinc superoxide dismutase and ALS. Adv Exp Med Biol 1999; 448: 193-203.
272. Goto JJ, Zhu H, Sanchez RJ, et al. Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem 2000; 275: 1007-14.
273. Singh RJ, Goss SP, Joseph J, et al. Nitration of gamma-tocopherol and oxidation of alpha-tocopherol by copper-zinc superoxide dismutase/H2O2/NO2-: role of nitrogen dioxide free radical. Proc Natl Acad Sci USA 1998; 95: 12912-7.
274. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999; 286: 2498-500.
275. Subramaniam JR, Lyons WE, Liu J, et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 2002; 5: 301-7.
276. Corson LB, Strain JJ, Culotta VC, et al. Chaperone-facillitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Nat Acad Sci USA 1998; 95: 6361-6.
277. McLoughlin DM, Standen CL, Lau KF, et al. The neuronal adaptor protein X11alpha interacts with the copper chaperone for SOD1 and regulates SOD1 activity. J Biol Chem 2001; 276: 9303-7.
278. Alonso DO, DeArmond SJ, Cohen FE, et al. Mapping the early steps in the pH-induced conformational conversion of the prion protein. Proc Natl Acad Sci USA 2001; 98: 2985-9.
279. Bailleul-Winslett PA, Newnam GP, Wegrzyn RD, et al. An antiprion effect of the anticytoskeletal drug latrunculin A in yeast. Gene Expr 2000; 9: 145-56.
280. Hornshaw MP, McDermott JR, Candy JM. Copper binding to the N-terminal tandem repeat regions of mammalian and avian prion protein. Biochem Biophys Res Commun 1995; 207: 621-9.
281. Bonomo RP, Imperllizzeri G, Pappalardo G, et al. Copper(II) binding modes in the prion octapeptide PHGGGWGQ: a spectroscopic and voltammetric study. Chemistry 2000; 6: 4195-202.
282. Ruiz FH, Silva E, Inestrosa NC. The N-terminal tandem repeat region of human prion protein reduces copper: role of tryptophan residues. Biochem Biophys Res Commun 2000; 269: 491-5.
283. Brown DR, Clive C, Haswell SJ. Antioxidant activity related to copper binding of native prion protein. J Neurochem 2001; 76: 69-76.
284. Kretzschmar HA, Tings T, Madlung A, et al. Function of PrP(C) as a copper-binding protein at the synapse. Arch Virol Suppl 2000; 16: 239-49.
285. Pauly PC, Harris DA. Copper stimulates endocytosis of the prion protein. J Biol Chem 1998; 273: 33107-10.
286. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 1999; 6: 436-58.
287. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
288. McAuslan BR, Gole GA. Cellular and molecular mechanisms in angiogenesis. Trans Ophthalmol Soc UK 1980; 100: 354-8.
289. Gullino PM. Considerations on the mechanism of the angiogenic response. Anticancer Res 1986; 6: 153-8.
290. Hu GF. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 1998; 69: 326-35.
291. Hannan GN, McAuslan BR. Modulation of synthesis of specific proteins in endothelial cells by copper, cadmium, and disulfiram: an early response to an angiogenic inducer of cell migration. J Cell Physiol 1982; 111: 207-12.
292. Ahmed Z, Idowu BD, Brown RA. Stabilization of fibronectin mats with micromolar concentrations of copper. Biomaterials 1999; 20: 201-9.
293. Sen CK, Khanna S, Venojarvi M, et al. Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol 2002; 282: H1821-7.
294. Brem SS, Zagzag D, Tsanaclis AMC, et al. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990; 137: 1121-42.
295. Yoshida D, Ikeda Y, Nakazawa S. Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995; 37: 287-92.
296. Moriguchi M, Nakajima T, Kimura H, et al. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 2002; 102: 445-52.
297. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002; 62: 4854-9.
298. Schuschke DA, Reed MW, Saari JT, et al. Short-term dietary copper deficiency does not inhibit angiogenesis in tumours implanted in striated muscle. Br J Cancer 1992; 66: 1059-64.
299. Cox C, Teknos TN, Barrios M, et al. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001; 111: 696-701.
300. Terrell GE, Swain JL. Indirect angiogenic agents do not release fibroblast growth factors from extracellular matrix. Matrix 1991; 11: 108-14.
301. McAuslan BR, Reilly W. Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res 1980; 130: 147-57.
302. Parke A, Bhattacherjee P, Palmer RMJ, et al. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 1988; 130: 173-8.
303. Lane TF, Iruela-Arispe ML, Johnson RS, et al. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994; 125: 929-43.
304. Soncin F, Guitton JD, Cartwright T, et al. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem Biophys Res Commun 1997; 236: 604-10.
305. Engleka KA, Maciag T. Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation. J Biol Chem 1992; 267: 11307-15.
306. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000; 6: 1-10.